TrialClinical and experimental nephrology2020

A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.

Tatsuo Hosoya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.